June 15, 2016
Pieris Pharmaceuticals raises a $16,500,000 corporate funding round from Biotechnology Value Fund.
Documentaries, videos and podcasts
April 26, 2021
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Boston Pharmaceuticals today announced that the companies have entered into an exclusive product license agreement to develop PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein
April 10, 2021
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa